GeneCentric

GeneCentric is a precision oncology company transforming cancer diagnostics and genomic profiling through the power of gene expression. With a foundation built on over a decade of research into gene expression, including the PurIST® test (commercially available through Tempus), GeneCentric has pioneered ExpressCT™, a proprietary technology that enables gene expression inference directly from circulating tumor DNA (ctDNA). This innovation is embodied in the GenomicsNext™ platform, a multimodal liquid biopsy solution that simultaneously detects DNA alterations and inferred gene expression from a single blood sample. Unlike traditional liquid biopsy alteration testing that focus solely on static DNA mutations, GenomicsNext™ unlocks dynamic, functional insights into the tumor’s “on state,” enhancing biomarker discovery, therapy selection, and clinical trial enrichment. GeneCentric partners with biopharma, diagnostic developers, and researchers to enable expression-driven companion diagnostics, particularly for emerging therapies like antibody-drug conjugates (ADCs), and to develop novel blood-based biomarkers that address current gaps in cancer care. Through its cutting-edge technology and deep expertise, GeneCentric is expanding the boundaries of what ctDNA can reveal and advancing the next generation of precision medicine.